Second, VEGFR-specific CD8+ T cells induced by our peptide-based vaccine may be able to kill not only VEGFR-expressing glioma endothelial cells but also glioma cells, based on the evidence for the existence of tumoral VEGFR1/VEGFR2 expression [24, 25, 47]. The gene discussed is CD8A; the disease is glioma.